Skip to Primary Navigation

Skip to main content

FDA to consider relaxing restrictions for peptides

A photo of US Department of Health and Human Services Secretary Robert F. Kennedy, Jr. speaking at a podium.
US Department of Health and Human Services Secretary Robert F Kennedy, Jr. Photo: Michael M. Santiago/Getty Images

Kevin Kinsella

2 min read
 Click to share on Facebook (Opens in new window/tab) Click to share on Twitter (Opens in new window/tab) Click to share on LinkedIn (Opens in new window/tab) Click to share on WhatsApp (Opens in new window/tab)

The regulator said it is looking to take seven peptides off a restrictive list for unapproved drugs considered too risky.

Federal regulation is supposed to be the opposite of “Wild West” antics, but that is what critics are calling the latest news out of the US Food and Drug Administration (FDA), even as MAHA influencers are cheering it on.

The FDA is weighing whether to relax restrictions on more than

Register for free to keep reading

To continue reading this article and unlock full access to GRIP, register now. You’ll enjoy free access to all content until our subscription service launches in early 2026.

  • Unlimited access to industry insights
  • Stay on top of key rules and regulatory changes with our Rules Navigator
  • Ad-free experience with no distractions
  • Regular podcasts from trusted external experts
  • Fresh compliance and regulatory content every day
Register for free
Sign in
, , , , , ,